Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434843 | 0.78 | MPI (0.38) | MPISMPD1 | |
| SCHEMBL17923999 | 0.78 | LPAR2 (0.36) | SMPD1 | |
| SCHEMBL17964308 | 0.76 | SMPD1 (0.34) | SMPD1 | |
| SCHEMBL2725372 | 0.76 | SMPD1 (0.35) | MPISMPD1 | |
| SCHEMBL17964306 | 0.74 | SMPD1 (0.36) | SMPD1 | |
| SCHEMBL6045766 | 0.72 | MPI (0.37) | MPISMPD1 | |
| Glycerylphosphate SCHEMBL59773 | 0.70 | SMPD1 (0.37) | SMPD1FDPSBLMTDP1 | |
| SCHEMBL6429913 | 0.70 | PTPN1 (0.38) | MPI | |
| SCHEMBL139867 | 0.70 | PTPN1 (0.38) | MPI | |
| SCHEMBL7639200 | 0.70 | PTPN1 (0.38) | MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230078330-A1 | HUMAN ANTI-DENGUE ANTIBODIES AND METHODS OF USE THEREFOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA PUBLIC CORPORATION | 2023-03-16 | — | — | US | disclosed |
| WO-2021154530-A1 | HUMAN ANTI-DENGUE ANTIBODIES AND METHODS OF USE THEREFOR | VANDERBILT UNIVERSITY (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-3307069-B1 | USE OF TELMISARTAN TO PREVENT AND TREAT GRAFT VERSUS HOST DISEASE AND OTHER ALLOIMMUNE AND AUTOIMMUNE DISEASES | UNIV HACKENSACK MEDICAL CENTER (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3307069-A1 | USE OF TELMISARTAN TO PREVENT AND TREAT GRAFT VERSUS HOST DISEASE AND OTHER ALLOIMMUNE AND AUTOIMMUNE DISEASES | Hackensack University Medical Center (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9937154-B2 | Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases | Hackensak University Medical Center (US) | 2018-04-10 | — | — | US | disclosed |
| WO-2016200694-A1 | USE OF TELMISARTAN TO PREVENT AND TREAT GRAFT VERSUS HOST DISEASE AND OTHER ALLOIMMUNE AND AUTOIMMUNE DISEASES | HACKENSACK UNIVERSITY MEDICAL CENTER (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160361300-A1 | USE OF TELMISARTAN TO PREVENT AND TREAT GRAFT VERSUS HOST DISEASE AND OTHER ALLOIMMUNE AND AUTOIMMUNE DISEASES | HACKENSACK UNIVERSITY MEDICAL CENTER | 2016-12-15 | — | — | US | disclosed |
| EP-1652928-B1 | PLANT PRODUCING HYALURONIC ACID | TOYO BOSEKI (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7547819-B2 | Plant producing hyaluronic acid | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20060168690-A1 | Plant producing hyaluronic acid | RESEARCH CENTER OF TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1652928-A1 | PLANT PRODUCING HYALURONIC ACID | Toyo Boseki Kabushiki Kaisha (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6699837-B2 | HEPATOCYTE GROWTH FACTOR MANUFACTURED BY GENE RECOMBINATION; TREATMENT OF DEMENTIA, SENILE DEMENTIA OF ALZHEIMER TYPE, CEREBRAL STROKE, AND CEREBRAL INFARCTION | NAKAMURA TOSHIKAZU (JP) | 2004-03-02 | — | — | US | disclosed |
| EP-0722737-B1 | Use of HGF for the preparation of a medicament against CNS disorders | SUMITOMO PHARMA (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-20030060403-A1 | THERAPEUTIC AGENT FOR DISORDER IN BRAIN AND NERVE | NAKAMURA TOSHIKAZU (JP) | 2003-03-27 | — | — | US | disclosed |
| US-20020049151-A1 | Therapeutic approaches to diseases by suppression of the NURR subfamily of nuclear transcription factors | BAYLOR COLLEGE OF MEDICINE | 2002-04-25 | — | — | US | disclosed |
| US-6099857-A | LIPID, VESICLE KIT; DRUG DELIVERY | WASHINGTON UNIVERSITY (US) | 2000-08-08 | — | — | US | disclosed |
| US-5766626-A | VESICLE COMPOSITION FOR DELIVERING THERAPEUTIC AGENT TO TARGET BIOLOGICAL CELLS | WASHINGTON UNIVERSITY (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0722737-A1 | REMEDY FOR CRANIAL NERVE DISORDER | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-07-24 | — | — | EP | disclosed |
| WO-1995031183-A1 | CELL MEMBRANE FUSION COMPOSITION AND METHOD | WASHINGTON UNIVERSITY (US) | 1995-11-23 | — | — | WO | disclosed |